New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 14, 2017 – AstraZeneca announced the FDA approval of Fasenra (benralizumab), for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Download PDF
Return to publications
